Healthcare Services
Valuation | |
|---|---|
| Market Cap | 32.68 kCr |
| Price/Earnings (Trailing) | 98.41 |
| Price/Sales (Trailing) | 7.13 |
| EV/EBITDA | 35.94 |
| Price/Free Cashflow | 459.69 |
| MarketCap/EBT | 61.05 |
| Enterprise Value | 33.13 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 5.2% |
| Price Change 1M | 11% |
| Price Change 6M | 4.7% |
| Price Change 1Y | 51.2% |
| 3Y Cumulative Return | 40% |
| 5Y Cumulative Return | 33.2% |
| 7Y Cumulative Return | 22.6% |
Cash Flow & Liquidity | |
|---|---|
| Revenue (TTM) |
| 4.58 kCr |
| Rev. Growth (Yr) | 12.1% |
| Earnings (TTM) | 359.06 Cr |
| Earnings Growth (Yr) | -8.9% |
Profitability | |
|---|---|
| Operating Margin | 13% |
| EBT Margin | 12% |
| Return on Equity | 7.53% |
| Return on Assets | 4.6% |
| Free Cashflow Yield | 0.22% |
| Cash Flow from Investing (TTM) |
| 6.01 kCr |
| Cash Flow from Operations (TTM) | 425.05 Cr |
| Cash Flow from Financing (TTM) | -6.36 kCr |
| Cash & Equivalents | 195.59 Cr |
| Free Cash Flow (TTM) | 79.01 Cr |
| Free Cash Flow/Share (TTM) | 1.52 |
Balance Sheet | |
|---|---|
| Total Assets | 7.81 kCr |
| Total Liabilities | 3.04 kCr |
| Shareholder Equity | 4.77 kCr |
| Current Assets | 1.88 kCr |
| Current Liabilities | 892.95 Cr |
| Net PPE | 3.73 kCr |
| Inventory | 92.4 Cr |
| Goodwill | 264.12 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.08 |
| Debt/Equity | 0.13 |
| Interest Coverage | 3.27 |
| Interest/Cashflow Ops | 4.39 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 5 |
| Dividend Yield | 0.79% |
| Shares Dilution (1Y) | 3.7% |
| Shares Dilution (3Y) | 3.7% |
Past Returns: Outperforming stock! In past three years, the stock has provided 40% return compared to 12.8% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 8% is a good sign.
Momentum: Stock price has a strong positive momentum. Stock is up 11% in last 30 days.
Size: Market Cap wise it is among the top 20% companies of india.
No major cons observed.
Past Returns: Outperforming stock! In past three years, the stock has provided 40% return compared to 12.8% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 8% is a good sign.
Momentum: Stock price has a strong positive momentum. Stock is up 11% in last 30 days.
Size: Market Cap wise it is among the top 20% companies of india.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.79% |
| Dividend/Share (TTM) | 5 |
| Shares Dilution (1Y) | 3.7% |
| Earnings/Share (TTM) | 6.41 |
Financial Health | |
|---|---|
| Current Ratio | 2.1 |
| Debt/Equity | 0.13 |
Technical Indicators | |
|---|---|
| RSI (14d) | 77.71 |
| RSI (5d) | 85.68 |
| RSI (21d) | 65.97 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Sell |
| SharesGuru Signal | Buy |
| RSI Signal | Sell |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Summary of Aster DM Healthcare's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
In the recent earnings call for Q3 FY26, Aster DM Healthcare's management provided a positive outlook, underpinned by strong operating performance and strategic growth plans. The management highlighted a combined proforma revenue growth of 15% year-on-year, reaching INR 2,366 crore, driven by a 9% increase in total patient volumes and an 8% rise in Inpatient Average Revenue Per Patient (ARPP). Operating EBITDA grew 22% year-on-year to INR 503 crore with an operating EBITDA margin of 21%.
The management noted that they added over 560 beds, bringing total capacity to 10,620+ beds, with plans for significant future expansions that include an additional 4,000 beds. The merger with Quality Care India Limited (QCIL) is progressing, with completion expected in Q1 FY27, as regulatory approvals are in place.
Major forward-looking points include:
Management emphasized the importance of execution discipline and building a scalable healthcare network, reinforcing their commitment to creating long-term stakeholder value.
Understand Aster DM Healthcare ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Union Investments Private Limited | 36.06% |
| Rimco (Mauritius) Limited | 6.87% |
| Kotak Small Cap Fund | 4.45% |
| Union (Mauritius) Holdings Limited | 3.86% |
| Bcp Asia Ii Topco Iv Pte.Ltd. | 2.69% |
| Quant Mutual Fund - Quant Small Cap Fund | 2.27% |
| Rashid Aslam Bin Mohideen Mammu Haji |
Detailed comparison of Aster DM Healthcare against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprises | 1.09 LCr | 24.42 kCr | +11.60% | +19.20% | 60.76 | 4.48 | - | - |
| MAXHEALTH | Max Healthcare Institute |
Comprehensive comparison against sector averages
ASTERDM metrics compared to Healthcare
| Category | ASTERDM | Healthcare |
|---|---|---|
| PE | 98.41 | 62.08 |
| PS | 7.13 | 6.31 |
| Growth | 8.2 % | 16.9 % |
Aster DM Healthcare is a prominent healthcare company that operates under the stock ticker ASTERDM, with a market capitalization of Rs. 25,627.5 Crores.
The company provides a wide range of healthcare and allied services across several countries, including India, the United Arab Emirates, Qatar, Oman, the Kingdom of Saudi Arabia, Jordan, Kuwait, Bahrain, and the Republic of Mauritius.
Aster DM Healthcare operates through various segments:
The company manages hospitals that include in-house pharmacies, as well as clinics equipped with in-house pharmacies. Additionally, it operates retail and online pharmacies and optical outlets. Aster DM Healthcare is also involved in offering healthcare consultancy and other related services.
Founded in 1987 and headquartered in Dubai, United Arab Emirates, Aster DM Healthcare reported a revenue of Rs. 4,232.7 Crores over the trailing 12 months. It is a profitable entity, having generated a profit of Rs. 5,320.2 Crores in the past four quarters.
The company rewards its investors by distributing a dividend, sporting a dividend yield of 24.17% per year, with a return of Rs. 124 dividend per share in the last twelve months.
In terms of growth, Aster DM Healthcare experienced a -57.6% revenue decline over the past three years, indicating some challenges in its financial performance during this period.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
ASTERDM vs Healthcare (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Here are the major questions and detailed answers from the Q&A section of the Aster DM Healthcare Q3 FY26 earnings conference call:
Question: "Can you give us more color on the performance of Aster Medcity, especially how much delta has been driven by the MVT volumes and whether this growth in the MVT is sustainable or not?"
Answer: "Aster Medcity has shown over 20% growth this quarter, primarily due to improved leadership and engagement with international patients. The MVT volumes grew by 64%, reflecting strong ties with patients from the Maldives and Oman. This growth is sustainable as we've successfully addressed previous setbacks, re-engaging these markets. Our flagship hospital consistently contributes around INR 90 crores monthly. Overall, you can expect continued strength across the Kerala cluster."
Question: "What is the expected timeline for the normalization of business in the Karnataka cluster after recent clinician movements?"
Answer: "While we've experienced a decline in occupancy to 55%, ARPP IP has grown by 17%, showing strong performance. We're making proactive hiring efforts and onboarding top clinicians. Most of the clinicians who left are seeking to return, indicating our good work environment. We anticipate normalized business performance soon, particularly as we've replaced critical positions with renowned specialists, enhancing our service and growth capabilities."
Question: "What levels of ARPOB can we anticipate in Bangalore moving forward, specifically for mature hospitals?"
Answer: "We believe there's room to grow. I see ARPOB potentially moving from the current INR 77,000 to about INR 75,000-80,000 in mature hospitals, given our focus on achieving higher complexity in care and ensuring better patient outcomes. We will continue improving our CONGO-T mix, which will help drive ARPOB."
Question: "Is the improvement in QCIL margins solely driven by QCIL efforts, or are there also impacts from synergies we've started realizing?"
Answer: "Yes, while we are seeing good numbers, the margins are mainly driven by synergies within QCIL, particularly between KIMS and other units like CARE. The synergies with Aster will only be evident post-merger, but the internal improvements we've implemented have significantly contributed to this outcome."
Question: "How do you see the future growth trajectory and profitability of the Kasargod unit?"
Answer: "The Kasargod hospital has ramped up well, currently averaging 400 patients daily. Losses have significantly reduced, and we expect to break even within the next quarter. We've established a solid clinical foundation with over 100 clinicians onboard. Given its performance trends, we remain optimistic about its growth trajectory."
Question: "What are your expectations regarding the reduction of ALOS in the merged entity compared to current levels?"
Answer: "The current ALOS is around 3.9 days. With strategic investments into complex procedures and enhanced oncology services, we anticipate this to continue decreasing. The interoperability of our resources post-merger will help create efficiencies that reduce ALOS and enhance overall patient care."
Each answer maintains the integrity of original data and provides insights into financial outlook and operational updates.
| 2.17% |
| Smallcap World Fund, Inc | 1.94% |
| Uti Small Cap Fund | 1.28% |
| Shamsudheen Bin Mohideenmammuhaji | 1.09% |
| Azad Moopen Mandayapurath | 0.28% |
| Alisha Moopen | 0.06% |
| Zeba Azad Moopen | 0.05% |
| Naseera Azad | 0.05% |
| Ziham Moopen | 0.03% |
Distribution across major stakeholders
Distribution across major institutional holders
| 1.06 LCr |
| 8.3 kCr |
| +8.30% |
| +5.40% |
| 74.51 |
| 12.75 |
| - |
| - |
| FORTIS | Fortis Healthcare | 69.53 kCr | 8.84 kCr | +9.10% | +51.00% | 72.41 | 7.87 | - | - |
| NH | Narayana Hrudayalaya | 37.34 kCr | 6.88 kCr | +0.70% | +30.10% | 47.64 | 5.43 | - | - |
| KIMS | Krishna Institute of Medical Sciences | 27.53 kCr | 3.65 kCr | +12.80% | +26.90% | 91.73 | 7.55 | - | - |
| -22.8% |
| 140 |
| 181 |
| 147 |
| 127 |
| 129 |
| 161 |
| Exceptional items before tax | -2053.7% | -28.29 | -0.36 | -4.39 | -26.42 | -23.72 | 0 |
| Total profit before tax | -38.3% | 112 | 181 | 142 | 101 | 105 | 161 |
| Current tax | 26.1% | 59 | 47 | 44 | 18 | 31 | 46 |
| Deferred tax | -687% | -14.74 | -1 | -1.1 | -13.01 | 6.7 | 6.39 |
| Total tax | -4.4% | 44 | 46 | 43 | 5 | 37 | 53 |
| Total profit (loss) for period | -51.7% | 59 | 121 | 94 | 86 | 64 | 106 |
| Other comp. income net of taxes | -286.1% | -2.05 | 0.21 | -0.4 | -1.99 | -0.05 | -0.09 |
| Total Comprehensive Income | -53.7% | 57 | 122 | 93 | 84 | 64 | 106 |
| Earnings Per Share, Basic | -98.2% | 1.02 | 2.13 | 1.67 | 1.59 | 1.14 | 1.94 |
| Earnings Per Share, Diluted | -98.2% | 1.02 | 2.13 | 1.67 | 1.58 | 1.14 | 1.94 |
| 10.4% |
| 86 |
| 78 |
| 52 |
| 44 |
| 36 |
| 33 |
| Depreciation and Amortization | 20% | 145 | 121 | 104 | 99 | 95 | 89 |
| Other expenses | 8.8% | 1,032 | 949 | 689 | 520 | 375 | 371 |
| Total Expenses | 11.6% | 2,094 | 1,876 | 1,401 | 1,109 | 836 | 810 |
| Profit Before exceptional items and Tax | 2767.3% | 5,965 | 209 | 182 | 90 | -68.04 | 65 |
| Exceptional items before tax | - | 323 | 0 | 0 | 0 | 0 | 0 |
| Total profit before tax | 2922.6% | 6,288 | 209 | 182 | 90 | -68.04 | 65 |
| Current tax | - | 75 | 0 | 33 | 0 | 0 | 3.87 |
| Deferred tax | -93.2% | 4.46 | 52 | -23.88 | -0.22 | 0.74 | 0.13 |
| Total tax | 52.9% | 79 | 52 | 9.04 | -0.22 | 0.74 | 4 |
| Total profit (loss) for period | 3879.5% | 6,209 | 157 | 173 | 90 | -68.78 | 61 |
| Other comp. income net of taxes | -23.8% | -1.03 | -0.64 | 0.41 | 0.46 | 0.01 | -0.25 |
| Total Comprehensive Income | 3904.5% | 6,208 | 156 | 174 | 91 | -68.77 | 60 |
| Earnings Per Share, Basic | 5652.1% | 124.67 | 3.15 | 3.48 | 1.81 | -1.38 | 1.21 |
| Earnings Per Share, Diluted | 5645.1% | 124.52 | 3.15 | 3.48 | 1.81 | -1.38 | 1.21 |
| 1.9% |
| 56 |
| 55 |
| 74 |
| 39 |
| 64 |
| 67 |
| Non-current investments | 110.9% | 2,127 | 1,009 | 720 | 720 | 2,170 | 2,141 |
| Loans, non-current | 13% | 357 | 316 | 501 | 455 | 429 | 353 |
| Total non-current financial assets | 83.6% | 2,634 | 1,435 | 1,307 | 1,261 | 2,658 | 2,565 |
| Total non-current assets | 37.4% | 4,608 | 3,353 | 3,193 | 2,768 | 4,126 | 3,787 |
| Total assets | 23.3% | 6,122 | 4,965 | 4,980 | 4,538 | 4,462 | 4,102 |
| Borrowings, non-current | -10.1% | 268 | 298 | 1,023 | 251 | 242 | 193 |
| Total non-current financial liabilities | 2.4% | 1,132 | 1,105 | 1,023 | 692 | 685 | 541 |
| Provisions, non-current | 21.4% | 18 | 15 | 15 | 11 | 11 | 8.42 |
| Total non-current liabilities | 2.1% | 1,229 | 1,204 | 1,130 | 780 | 715 | 566 |
| Borrowings, current | -5.1% | 75 | 79 | 92 | 135 | 167 | 147 |
| Total current financial liabilities | 9% | 413 | 379 | 385 | 424 | 466 | 387 |
| Provisions, current | 56.1% | 1.89 | 1.57 | 1.58 | 1.58 | 1.25 | 1.25 |
| Total current liabilities | 8.8% | 458 | 421 | 426 | 464 | 502 | 406 |
| Total liabilities | 3.8% | 1,687 | 1,625 | 1,556 | 1,243 | 1,217 | 972 |
| Equity share capital | 3.6% | 518 | 500 | 500 | 500 | 500 | 500 |
| Total equity | 32.8% | 4,435 | 3,339 | 3,424 | 3,294 | 3,245 | 3,131 |
| Total equity and liabilities | 23.3% | 6,122 | 4,965 | 4,980 | 4,538 | 4,462 | 4,102 |
| -2.3% |
| 434 |
| 444 |
| 262 |
| 36 |
| - |
| - |
| Income taxes paid (refund) | 109.7% | 66 | 32 | 16 | 4.4 | - | - |
| Net Cashflows From Operating Activities | -11.2% | 367 | 413 | 246 | 32 | - | - |
| Cashflows used in obtaining control of subsidiaries | -103% | 0 | 34 | 65 | 15 | - | - |
| Proceeds from sales of PPE | -80.7% | 1.11 | 1.57 | 0.17 | 0.17 | - | - |
| Purchase of property, plant and equipment | -36% | 138 | 215 | 158 | 46 | - | - |
| Purchase of intangible assets | -120% | 0.56 | 0.8 | 2.37 | 1.01 | - | - |
| Dividends received | 80961% | 5,578 | 7.88 | 7.41 | 55 | - | - |
| Interest received | 15933.3% | 58 | 0.64 | 0.55 | 0.88 | - | - |
| Other inflows (outflows) of cash | -2885700% | -1,153.32 | 0.96 | -1.07 | 3.14 | - | - |
| Net Cashflows From Investing Activities | 1854% | 6,023 | -342.32 | -331.95 | -3.35 | - | - |
| Proceeds from issuing shares | - | 3.09 | 0 | 0 | 0.58 | - | - |
| Proceeds from borrowings | -0.8% | 125 | 126 | 166 | 30 | - | - |
| Repayments of borrowings | 72.7% | 134 | 78 | 24 | 0.26 | - | - |
| Payments of lease liabilities | 5.3% | 80 | 76 | 30 | 31 | - | - |
| Dividends paid | - | 6,174 | 0 | 0 | 0 | - | - |
| Interest paid | -2.6% | 38 | 39 | 20 | 17 | - | - |
| Net Cashflows from Financing Activities | -9151.2% | -6,298.11 | -67.09 | 92 | -17.11 | - | - |
| Net change in cash and cash eq. | 3788.9% | 92 | 3.34 | 6.11 | 11 | - | - |
Analysis of Aster DM Healthcare's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Hospitals | 97.6% | 1.2 kCr |
| Wholesale Pharmacies | 1.7% | 20.4 Cr |
| Clinics | 0.7% | 8.3 Cr |
| Total | 1.2 kCr |
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years